Totah RA, Rettie AE. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther. 2005;77:341–52.

Article  CAS  PubMed  Google Scholar 

Zhou Y, Lauschke VM. The genetic landscape of major drug metabolizing cytochrome P450 genes—an updated analysis of population-scale sequencing data. Pharmacogenomics J. 2022;22:284–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gréen H, Söderkvist P, Rosenberg P, Mirghani RA, Rymark P, Lundqvist EÅ, et al. Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol. 2009;104:130–7.

Article  PubMed  Google Scholar 

Parikh S, Ouedraogo J, Goldstein JA, Rosenthal PJ, Kroetz DL. Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther. 2007;82:197–203.

Article  CAS  PubMed  Google Scholar 

Pernaute-Lau L, Morris U, Msellem M, Mårtensson A, Björkman A, Gil JP. Influence of cytochrome P450 (CYP) 2C8 polymorphisms on the efficacy and tolerability of artesunate-amodiaquine treatment of uncomplicated plasmodium falciparum malaria in Zanzibar. Malar J. 2021;20:90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics. 2001;11:597–607.

Article  CAS  PubMed  Google Scholar 

Gao Y, Liu D, Wang H, Zhu J, Chen C. Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug–drug interactions. Xenobiotica. 2010;40:467–75.

Article  CAS  PubMed  Google Scholar 

Yu L, Shi D, Ma L, Zhou Q, Zeng S. Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013;34:278–87.

Article  PubMed  Google Scholar 

Tsukada C, Saito T, Maekawa M, Mano N, Oda A, Hirasawa N, et al. Functional characterization of 12 allelic variants of CYP2C8 by assessment of paclitaxel 6α-hydroxylation and amodiaquine N-deethylation. Drug Metab Pharmacokinet. 2015;30:366–73.

Article  CAS  PubMed  Google Scholar 

García-Martín E, Martínez C, Ladero JM, Agúndez JAG. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther. 2006;10:29–40.

Article  PubMed  Google Scholar 

Paganotti GM, Gramolelli S, Tabacchi F, Russo G, Modiano D, Coluzzi M, et al. Distribution of human CYP2C8*2 allele in three different African populations. Malar J. 2012;11:125.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide Distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther. 2017;102:688–700.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pernaute-Lau L, Camara M, de Sousa TN, Morris U, Ferreira MU, Gil JP. An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria. Expert Opin Drug Metab Toxicol. 2022;18:39–59.

Article  CAS  PubMed  Google Scholar 

Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581:434–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aquilante CL, Niemi M, Gong L, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. Pharmacogenet Genomics. 2013;23:721–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Soyama A, Saito Y, Komamura K, Ueno K, Kamakura S, Ozawa S, et al. Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift. Drug Metab Pharmacokinet. 2002;17:374–7.

Article  CAS  PubMed  Google Scholar 

Hichiya H, Tanaka-Kagawa T, Soyama A, Jinno H, Koyano S, Katori N, et al. Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population. Drug Metab Dispos. 2005;33:630–6.

Article  CAS  PubMed  Google Scholar 

Saito Y, Katori N, Soyama A, Nakajima Y, Yoshitani T, Kim S-R, et al. CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population. Pharmacogenet Genomics. 2007;17:461–71.

Article  CAS  PubMed  Google Scholar 

Singh R, Ting JG, Pan Y, Teh LK, Ismail R, Ong CE. Functional role of Ile264 in CYP2C8: mutations affect haem incorporation and catalytic activity. Drug Metab Pharmacokinet. 2008;23:165–74.

Article  CAS  PubMed  Google Scholar 

Hanioka N, Matsumoto K, Saito Y, Narimatsu S. Influence of CYP2C8*13 and CYP2C8*14 alleles on amiodarone N-deethylation. Basic Clin Pharmacol Toxicol. 2011;108:359–62.

Article  CAS  PubMed  Google Scholar 

Lee M-Y, Apellniz-Ruiz M, Johansson I, Vikingsson S, Bergmann TK, Brøsen K, et al. Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity. Pharmacogenomics. 2015;16:929–37.

Article  CAS  PubMed  Google Scholar 

Aquilante CL, Kosmiski LA, Bourne DWA, Bushman LR, Daily EB, Hammond KP, et al. Impact of the CYP2C8 *3 polymorphism on the drug–drug interaction between gemfibrozil and pioglitazone. Br J Clin Pharmacol. 2013;75:217–26.

Article  CAS  PubMed  Google Scholar 

Tomalik-Scharte D, Fuhr U, Hellmich M, Frank D, Doroshyenko O, Jetter A, et al. Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. Drug Metab Dispos. 2011;39:927–32.

Article  CAS  PubMed  Google Scholar 

Jiang H, Zhong F, Sun L, Feng W, Huang Z-X, Tan X. Structural and functional insights into CYP2C83: a genetic polymorph of cytochrome P450 2C8. Amino Acids. 2011;40:1195–204.

Article  CAS  PubMed  Google Scholar 

Arnold WR, Zelasko S, Meling DD, Sam K, Das A. Polymorphisms of CYP2C8 alter first-electron transfer kinetics and increase catalytic uncoupling. Int J Mol Sci. 2019;20:4626.

Article  CAS  Google Scholar 

Daily EB, Aquilante CL. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009;10:1489–510.

Article  CAS  PubMed  Google Scholar 

Vicente M, Priehodova E, Diallo I, Podgorna E, Poloni ES, Cerny V, Schlebusch CM. Population history and genetic adaptation of the Fulani nomads: inferences from genome-wide data and the lactase persistence trait. BMC Genom. 2019;20:915.

Article  CAS  Google Scholar 

Modiano D, Petrarca V, Sirima SB, Nebie I, Diallo D, Esposito F, Coluzzi M. Different response to Plasmodium falciparum malaria in West African sympatric ethnic groups. Proc Natl Acad Sci USA. 1996;93:13206–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tiono AB, Sirima SB, Hamed K. Fulani show decreased susceptibility to Plasmodium falciparum infection versus Mossi: data from a community-wide screening and treatment of asymptomatic carriers in Burkina Faso. Malar J. 2013;12:163.

Article  PubMed  PubMed Central  Google Scholar 

Maiga B, Dolo A, Toure O, Dara V, Tapily A, Campino S, et al. Human candidate polymorphisms in sympatric ethnic groups differing in malaria susceptibility in Mali. PLoS ONE. 2013;8: e75675.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haeggström S, Ingelman-Sundberg M, Pääbo S, Zeberg H. The clinically relevant CYP2C8*3 and CYP2C9*2 haplotype is inherited from Neandertals. Pharmacogenomics J. 2022;22:247–9.

Article  PubMed  PubMed Central  Google Scholar 

Anvikar AR, Sharma B, Shahi BH, Tyagi PK, Bose TK, Sharma SK, et al. Artesunate-amodiaquine fixed dose combination for the treatment of Plasmodium falciparum malaria in India. Malar J. 2012;11:97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peto TJ, Tripura R, Callery JJ, Lek D, Nghia HDT, Nguon C, et al. Triple therapy with artemether–lumefantrine plus amodiaquine versus artemether–lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial. Lancet Infect Dis. 2022;22:867–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jewell H, Maggs JL, Harrison AC, O’Neill PM, Ruscoe JE, Park BK. Role of hepatic metabolism in the bioactivation and detoxication of amodiaquine. Xenobiotica. 1995;25:199–217.

Article  CAS  PubMed